Takeda Pharmaceutical Co Stock Today
| TAK Stock | USD 13.57 0.13 0.97% |
Performance0 of 100
| Odds Of DistressLess than 8
|
Takeda Pharmaceutical is selling for 13.57 as of the 28th of November 2024. This is a 0.97% increase since the beginning of the trading day. The stock's last reported lowest price was 13.44. Takeda Pharmaceutical has only a 8 % chance of going through financial distress over the next few years, but has generated negative returns over the last 90 days. Equity ratings for Takeda Pharmaceutical Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of October 2008 | Category Healthcare | Classification Health Care |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. The company has 3.17 B outstanding shares of which 5.66 M shares are at this time shorted by investors with about 3.88 days to cover. More on Takeda Pharmaceutical Co
Moving together with Takeda Stock
| 0.82 | VALN | Valneva SE ADR | PairCorr |
| 0.77 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.82 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.83 | LLY | Eli Lilly Sell-off Trend | PairCorr |
| 0.91 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Takeda Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Takeda Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Christophe Weber | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [Tap Oil Limited, Tap Oil Limited] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NYSE Composite, ARCA Pharmaceutical, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsTakeda Pharmaceutical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Takeda Pharmaceutical's financial leverage. It provides some insight into what part of Takeda Pharmaceutical's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Takeda Pharmaceutical Co (TAK) is traded on New York Stock Exchange in USA. It is located in 1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668 and employs 49,281 people. Takeda Pharmaceutical is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a total capitalization of 42.61 B. Takeda Pharmaceutical runs under Pharmaceuticals sector within Health Care industry. The entity has 3.17 B outstanding shares of which 5.66 M shares are at this time shorted by investors with about 3.88 days to cover.
Takeda Pharmaceutical Co has about 533.53 B in cash with 716.34 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 208.91, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Takeda Pharmaceutical Probability Of Bankruptcy
Ownership AllocationTakeda Pharmaceutical shows a total of 3.17 Billion outstanding shares. About 97.54 % of Takeda Pharmaceutical outstanding shares are held by general public with 0.009 (%) owned by insiders and only 2.45 % by institutional holders. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Takeda Ownership Details
Takeda Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Managed Asset Portfolios, Llc | 2024-09-30 | 1.6 M | |
| Envestnet Asset Management Inc | 2024-09-30 | 1.4 M | |
| Blackrock Inc | 2024-06-30 | 1.4 M | |
| Causeway Capital Management Llc | 2024-09-30 | 1.3 M | |
| Macquarie Group Ltd | 2024-06-30 | 1 M | |
| Wells Fargo & Co | 2024-06-30 | 871.7 K | |
| Bank Of America Corp | 2024-06-30 | 867.1 K | |
| Jane Street Group Llc | 2024-06-30 | 603.8 K | |
| Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 585.8 K | |
| Capital Research Global Investors | 2024-09-30 | 13.1 M | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10 M |
Takeda Pharmaceutical Historical Income Statement
Takeda Stock Against Markets
Takeda Pharmaceutical Corporate Directors
| JeanLuc Butel | Independent Director | Profile | |
| Michel Orsinger | Independent Director | Profile | |
| Shiro Kuniya | Independent Director | Profile | |
| Toshiyuki Shiga | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.